Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The semaglutide market has experienced significant growth ... Supply Chain and Production Challenges Due to surging demand, supply chain constraints have emerged, leading to product shortages ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

More recent case law has reinforced this principle, holding that when therapeutic and non-therapeutic effects are inseparably linked, merely limiting the claim to a "non-therapeutic use" or ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

JACKSON, WY / ACCESS Newswire / April 1, 2025 / Labor Smart, Inc. (OTC PINK:LTNC), through its newest subsidiary Elevate ...

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...

Semaglutide is no longer in shortage ... But that strategy could face some challenges ahead as Hims & Hers doesn't make top GLP-1 drugs. Instead, it has been able to connect patients to compounded ...